Skip to main content
Erschienen in: BMC Medicine 1/2010

Open Access 01.12.2010 | Research article

The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo

verfasst von: Jodie M Fleming, Tyler C Miller, Mariam Quinones, Zhen Xiao, Xia Xu, Matthew J Meyer, Erika Ginsburg, Timothy D Veenstra, Barbara K Vonderhaar

Erschienen in: BMC Medicine | Ausgabe 1/2010

Abstract

Background

Breast cancer studies frequently focus on the role of the tumor microenvironment in the promotion of cancer; however, the influence of the normal breast microenvironment on cancer cells remains relatively unknown. To investigate the role of the normal breast microenvironment on breast cancer cell tumorigenicity, we examined whether extracellular matrix molecules (ECM) derived from premenopausal African-American (AA) or Caucasian-American (CAU) breast tissue would affect the tumorigenicity of cancer cells in vitro and in vivo. We chose these two populations because of the well documented predisposition of AA women to develop aggressive, highly metastatic breast cancer compared to CAU women.

Methods

The effects of primary breast fibroblasts on tumorigenicity were analyzed via real-time PCR arrays and mouse xenograft models. Whole breast ECM was isolated, analyzed via zymography, and its effects on breast cancer cell aggressiveness were tested in vitro via soft agar and invasion assays, and in vivo via xenograft models. Breast ECM and hormone metabolites were analyzed via mass spectrometry.

Results

Mouse mammary glands humanized with premenopausal CAU fibroblasts and injected with primary breast cancer cells developed significantly larger tumors compared to AA humanized glands. Examination of 164 ECM molecules and cytokines from CAU-derived fibroblasts demonstrated a differentially regulated set of ECM proteins and increased cytokine expression. Whole breast ECM was isolated; invasion and soft agar assays demonstrated that estrogen receptor (ER)-, progesterone receptor (PR)/PR- cells were significantly more aggressive when in contact with AA ECM, as were ER+/PR+ cells with CAU ECM. Using zymography, protease activity was comparatively upregulated in CAU ECM. In xenograft models, CAU ECM significantly increased the tumorigenicity of ER+/PR+ cells and enhanced metastases. Mass spectrometry analysis of ECM proteins showed that only 1,759 of approximately 8,000 identified were in common. In the AA dataset, proteins associated with breast cancer were primarily related to tumorigenesis/neoplasia, while CAU unique proteins were involved with growth/metastasis. Using a novel mass spectrometry method, 17 biologically active hormones were measured; estradiol, estriol and 2-methoxyestrone were significantly higher in CAU breast tissue.

Conclusions

This study details normal premenopausal breast tissue composition, delineates potential mechanisms for breast cancer development, and provides data for further investigation into the role of the microenvironment in cancer disparities.
Begleitmaterial
Additional file 1: Supplementary table and figures. Table S1: Real-time PCR primer sequences. Figure S1. Tumor characterization. (a,b) Humanized murine mammary glands, injected with primary metastatic breast cancer cells were stained for Ki67 (a). Bar = 200 μm. Percentage proliferation: number of positive per total live cells in a minimum of three fields. (b) Representative hematoxylin and eosin (H&E)-stained section. Bar = 2,000 μm. Overt necrosis was determined using AxioVision Imaging software version 4.8. Data represent mean ± standard error. AA = African-American, CAU = Caucasian-American. Figure S2. Validation of qPCR arrays. Breast fibroblasts pools, derived from a minimum of three age-matched patients, were analyzed per array. Graphs represent fold increase of differentially regulated genes. Figure S3. Soft agar growth assay. Cell lines were assayed and stained with nitrobluetetrazolium before counting. Representative images of a minimum of two experiments per cell line. Bar = 200 μm. Figure S4. Representative MS/MS spectra of peptides identified from breast tissue ECM proteins. A = hornerin; B = wnt10a; C = vimentin; D = cytokeratin 19. Figure S5. In silico analysis in African-American extracellular matrix protein molecules. (a-d) Top signaling network of unique proteins. Mapped identifiers (shown in gray) were overlaid onto a global molecular network developed from information contained in the Ingenuity knowledge base. Networks were then algorithmically generated based on their connectivity and incorporated with other molecules with high connectivity (white). Nodes associated with breast cancer according to the IPA knowledge base, are utlined in yellow. Figure S6. In silico analysis in Caucasian-American extracellular matrix protein molecules. (a-d) As for Figure S5. (PPT 11 MB)
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1741-7015-8-27) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

BKV and JMF conceived the project and designed all experiments. JMF performed all experiments and wrote the manuscript in consultation with BKV. TCM assisted in animal studies and qRT-PCR. MQ performed IPA and proteomic computational analyses. ZX and XX developed and performed MS procedures. MJM performed FACS. EG edited the manuscript and assisted in experiments. TDV assisted in the design and method of all MS procedures. All authors contributed to the analysis of data.

Background

Breast cancer is the most frequently diagnosed cancer and the second leading cause of cancer-related deaths of women living in the US [1]. Breast cancer manifests itself in the mammary epithelium; however, tumors do not progress to malignancy in isolation. The local microenvironment can enhance or suppress tumor growth and progression, as well as metastases [28]. The stroma is composed of diverse cell types including endothelial and immune cells, adipocytes, and fibroblasts. These cells secrete products, including growth factors and extracellular matrix (ECM) components, which profoundly affect cell behavior. It has been suggested that altered communication between these cells can lead to the progression or expansion of malignant growth. While numerous studies have observed the effects of synthetic or mouse-derived ECM on breast cancer cells, relatively little is known about the molecular interactions between human breast ECM and epithelial cells.
Recently, a novel in vivo xenograft model mimicking human ductal carcinoma in situ (DCIS) illustrated that the progression of normal tissue towards a neoplastic state depends on the surrounding stromal cells [9]. Normal myoepithelial cells inhibited the progression of DCIS to an invasive carcinoma, while the addition of fibroblasts enhanced invasion. Additionally, reports demonstrated that the mammary microenvironment can reprogram both embryonic and adult murine stem cells into mammary cells capable of expressing milk proteins and hormone receptors, substantiating the remarkable control the environment has on cell behavior [10, 11].
African-American (AA) women have a lower overall incidence of breast cancer compared to Caucasian-American (CAU) women but a significantly higher incidence rate before the age of 40, and a higher mortality rate at any age [1]. Breast carcinomas in premenopausal AA patients are more often triple negative, which lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification [1215]. Triple-negative cancers constitute one of the most challenging types of breast cancer, as the only systemic therapy is chemotherapy.
It has been proposed that premenopausal AA women develop triple-negative tumors due to multifactorial differences including socioeconomic factors, body mass index, diet, earlier age at first pregnancy, lower incidence of breastfeeding, and higher breast density [16, 17]. However, these factors do not explain everything. A recent study reported that even after adjusting for socioeconomic status, AA women still have a 22% higher mortality rate [18]. Interestingly, there are parallels in carcinoma development between women in western African nations and AAs, including early onset of disease and hormone receptor negativity [19]. These women share common ancestry suggesting that mutations in breast cancer susceptibility genes are partly responsible for the high prevalence of triple-negative carcinomas [19]. This predisposition of AA women to develop a more aggressive cancer compared to CAU women provides a unique model for studying the role of the normal breast microenvironment on breast cancer development. Hence, our objective was to determine whether factors within the local microenvironment of premenopausal AA and CAU women differentially alter the behavior of breast cancer cells.
In this study, premenopausal AA or CAU primary breast fibroblasts and ECM from whole breast tissue were isolated and examined by several in vitro and in vivo methods. ER-/PR- cells were significantly more aggressive in the presence of AA ECM by both invasion and soft agar assays; in contrast, CAU ECM caused increased aggressiveness with ER+/PR+ cells. By mass spectrometry, approximately 22% of identified proteins were common to both AA-derived and CAU-derived ECM; proteins related to tumorigenesis/neoplasia were more highly associated with the AA ECM while proteins involved with growth/metastasis were more prevalent with the CAU ECM. Using a novel mass spectrometry assay to measure biologically active hormones, only estradiol, estriol, and 2-methoxyestrone levels were significantly higher in the CAU breast. Finally, in a xenograft model, CAU ECM significantly enhanced the tumorigenicity and metastases of ER+/PR+ cells. To our knowledge, we are the first to investigate the normal ECM of premenopausal women; furthermore, results from this study may help identify mechanisms by which AA are predisposed to developing a more aggressive breast cancer.

Methods

Collection and processing of patient samples

Collection of patient samples was performed in accordance with the guidelines of the National Cancer Institute Review Board, under four separate approved protocol numbers OH99-C-NO57, 02-C-0077E, 04-C-0199, and OHSR4789. Written informed consent was obtained from all human subjects as stipulated in the protocols. Breast tissue was collected from fasting, age-matched, premenopausal AA or CAU reduction mammoplasty patients. The tissue obtained for analyses was considered pathological medical waste; thus any clinical details of the women, apart from age and race, were unattainable. Overall, 53 AA and 50 CAU breast tissue samples, from patients with a median age of 29 years, were used for analyses. Race was self-reported by the patients. Tissue was collected from southern, eastern, and midwestern regions of the US. A pathologist confirmed that each patient was free of malignant or hyperplasic growth. Immediately after surgery a separate piece of tissue was used for isolation of primary human breast fibroblasts, and the remaining tissue was snap frozen and stored at -80°C for RNA and protein analyses, and for ECM isolation.
Pleural effusion cells were collected from a parous, 49-year-old Caucasian breast cancer patient with an ER+/PR+, Her2-, T1, pN1, M1, Grade 3, poorly differentiated invasive ductal carcinoma. Immediately following collection, cells were processed as follows: cells were gently pelleted by centrifugation, washed twice in Hank's buffered saline solution, frozen viably in dimethylsulfoxide (DMSO) Freeze media (Invitrogen; Gaithersburg, MD, USA) and stored in liquid nitrogen until used. The cells derived from the pleural effusion were ER-/PR- and Her2-, as determined by immunohistochemistry.

Fluorescent activated cytometric sorting (FACS)

Immediately prior to use, pleural effusion cells were stained with lineage markers to segregate tumor from non-tumor cells as previously described [20]. Briefly, lineage marker antibodies used were fluorescein conjugated anti-human CD2, CD3, CD10, CD16, CD18, CD31, CD64, and CD140b (BD Biosciences, San Jose, CA, USA). Cells were stained in a phosphate-buffered saline (PBS) solution containing 0.1% fetal bovine serum (FBS) and 100 units/ml penicillin/streptomycin for 25 min at 4°C. Cell sorting was performed on a BD FACSAria operating at low pressure (20 psi) using a 100 μm nozzle. Doublets were electronically gated out and 7-aminoactinomycin D (7AAD, 1 μg/ml final concentration, BD Biosciences) was used for live/dead cell distinction. Live, fluorescein negative tumor cells were sorted into a PBS solution containing 50% FBS. Post-sort analysis typically indicated purities of >96% with minimal cell death (<10%). FACS data were analyzed using FlowJo v8.7.3 (TreeStar, Ashland, OR, USA).

Cell culture

MCF10Ca1h cells (kind gift of FR Miller, Wayne State University, Detroit, MI, USA, through LM Wakefield, Center for Cancer Research (CCR), National Cancer Institute (NCI), Bethesda, MD, USA) were maintained as described previously [21]. All other cell lines were obtained from the American Type Culture Collection (ATCC; http://​www.​atcc.​org) and cultured according to the repository's instructions. Fibroblasts were isolated as described [22]. Briefly, <5 mm pieces of tissue were placed on a scratched cell culture dish. Tissue pieces were covered with a minimal amount of media and, with time, the fibroblasts crawled out of the tissue to form a monolayer on the dish. The fragments of tissue were removed and the remaining fibroblasts were passaged and plated as monolayer cultures to expand and ensure fibroblast purity. When necessary, epithelial cells were separated from the stromal cells by differential trypsinization and selective pressure with fibroblast growth medium. Fibroblasts were grown for a maximum of two passages prior to analysis.

Isolation of whole breast tissue ECM proteins

Extraction of human breast ECM from whole breast tissue was performed as previously described [23]. A minimum of three different age-matched patient samples per treatment group was used for each extraction (total n = 26 AA, and 21 CAU). Pools were necessary in order to obtain enough tissue from which to extract ECM. A different pool of samples was used for each experiment. Matrices were stored on ice at 4°C and used within 5 days of isolation.

Zymography

Equal amounts of protein were separated by gel electrophoresis in a 10% Tris-glycine polyacrylamide gel (Invitrogen) with 0.1% gelatin incorporated as a substrate. Proteins were renatured, soaked in developing buffer, and then stained according to the manufacturer's instructions. Matrix metalloproteinase (MMP) activity was visualized as clear bands against a dark blue background where the protease has digested the substrate. Identification of MMPs was based on published molecular weights. Three independent experiments, each with different pools of age-matched patient samples (minimum of three patient samples per pool), were performed with each individual experiment repeated in duplicate to ensure repeatability.

Invasion assay

Transwell membranes (8 μm pores) were precoated with equal amounts of ECM, adjusted for total protein content. Breast cancer cells were washed, resuspended in serum-free medium, and then plated in the top chamber of transwell inserts (at the predetermined concentration for each cell line). The cells were allowed to invade through the membrane for up to 16 h towards FBS-containing medium in the bottom chamber. Following invasion, the cells were wiped from the top surface of the membrane; the remaining cells were fixed in methanol and stained with a 1% toluidine blue solution. Four independent experiments, each with different pools of patient samples (minimum of three patient samples per pool), were performed with each individual experiment repeated in duplicate to ensure repeatability.

Soft agar assay

Breast cancer cells were plated on an 0.66% agarose base in a 0.33% top soft agar layer in 35 mm cell culture dishes with the addition or absence of 100 μl of ECM, adjusted for equal protein content. Cells were incubated for 10 to 12 days, and then stained overnight with nitrobluetetrazolium. The total number of colonies in each dish was counted using the AccuCount 1000 colony counter (BioLogics, Manassas, VA, USA); however, only colonies over 1 μm in diameter were included in the calculation. Three independent experiments, each with different pools of patient samples (minimum of three patient samples per pool), were performed with each individual experiment repeated in duplicate to ensure repeatability.

Immunohistochemistry

Immunohistochemistry was performed with appropriate controls as described previously [24]. Briefly, sections of formalin fixed, paraffin embedded tissue 5 μm thick were prepared from all tumors obtained in the xenograft studies, and fragments of the lungs and livers of animals used in the metastasis experiments. The human specific COXIV antibody (1:1,000, Cell Signaling; Boston, MA, USA) was used for detection of metastases of breast cancer cells in the xenograft experiments. Antibodies Ki67 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and ER (Leica Microsystems, Bannockburn, IL, USA) were used according to manufacturers' instructions. Staining was performed using Vectastain ABC kit (Vector Laboratories; Burlingame, CA, USA) according to the manufacturer's instructions. Color was developed with diaminobenzidine peroxidase substrate kit (Vector Laboratories) and sections were counterstained with hematoxylin.

Quantitative real-time (qRT) PCR and PCR arrays

Total RNA was isolated from primary breast fibroblasts using the Qiagen RNeasy kit according to the manufacturer's instructions (Valencia, CA, USA). RNA was reverse transcribed using MMLV reverse transcriptase (Invitrogen) and primed with oligo-dT and random hexamers (Invitrogen). The cDNA was subjected to RT-PCR amplification using gene specific primers and 2 × Brilliant II Sybr Green QPCR Mastermix (Stratagene, La Jolla, CA, USA). Primer sequences are given in Additional file 1: Table S1. Quantitative RT-PCR was analyzed via the ΔΔCT method, and PCR products were visualized by agarose gel electrophoresis. qRT-PCR arrays were performed and analyzed with the commercially available qRT-PCR array kits according to the manufacturer's instructions (SABiosciences, Frederick, MD, USA). Three pools of fibroblasts, each with a minimum of three different patient fibroblasts per pool, were used for each array (n = 9 AA and 10 CAU). Validation of the array data used different, freshly isolated individual primary fibroblasts (n = 9 AA and 9 CAU).

In vivotumor formation assays

Animal experiments were conducted in accord with accepted standards of humane animal care and approved by the Animal Care and Use Committee at the National Institutes of Health, USA. Female, 8-week-old athymic Nu/Nu mice, or NOD/SCID where indicated, were randomized into three groups with a minimum of five mice per group (APA, Frederick, MD, USA). Mice were anesthetized by an intraperitoneal injection of ketamine/xylazine (750 and 50 mg/kg body weight, respectively) in Hank's buffered saline solution (HBSS) prior to surgically exposing the gland for injection. NOD SCID mice were supplemented with estrogen via a subcutaneous pellet (0.72 mg β-estradiol, 90-day release, Innovative Research of America, Sarasota, FL, USA) at the time of breast cancer cell injection. For fibroblast studies, mouse abdominal mammary glands were humanized with primary human fibroblasts as previously described [25]. Each experiment used a minimum of three different patient pools of fibroblasts per humanization (total AA n = 12, CAU n = 14). Following humanization, primary metastatic breast cancer cells, derived from a pleural effusion, were sorted via FACS to remove non-epithelial cells, and then mixed with 1:1 ratio of 1 × PBS:Matrigel (BD Biosciences). A total of 30 μl of ECM containing 5 × 103 cells was injected into the humanized abdominal mammary gland fat pad. Tumor growth was measured using calipers on a weekly basis. Tumors were excised when the majority of tumors reach 1.0 cm3, and final tumor volume was calculated ((0.5 × L) × (0.5 × W) × (0.5 × H) × (4/3) × (π)).
For ECM studies, breast cancer cells (MDA-MB-231 and T47D) proliferating in log phase were mixed with control matrix (Matrigel), AA or CAU ECM, adjusted for equal protein content. A total of 40 μl of ECM containing 1 × 106 or 2 × 106 cells was injected, respectively, into the abdominal mammary fat pad or subcutaneously proximal to the scapula. Tumor growth was measured on a weekly basis using calipers. Tumors were excised using survival surgery when the majority of tumors reach 1.0 cm3, and final tumor volume was calculated. At 3 months post tumor excision, the animals were killed and the liver and lung tissues were removed for detection of metastases. Tissues were analyzed for metastases by pathological evaluation, quantitative PCR using human-specific primers developed to β2-microglobulin [26], and immunohistochemistry using a human specific COXIV antibody. Each animal experiment was repeated a minimum of two times, using different pools of ECM (minimum of three patients per pool) for each experiment.

Mass spectrometry

Three sets of pools of AA and CAU ECM, derived from different patients in each pool, minimum of three patients per pool, were quantified and 2 μg of ECM from each pool were separated on a 4% to 12% Nu-PAGE Bis-Tris gel in MOPS SDS running buffer (Invitrogen). The gel was washed and stained using SimplyBlue Safe Stain Solution (Invitrogen). Each gel lane was divided into 10 sections, excised, destained, lyophilized and digested with trypsin in 25 mM NH4HCO3, pH 8.4, overnight at 37°C. The tryptic peptides were extracted from gel slices using 70% acetonitrile containing 5% formic acid, lyophilized, and the peptides reconstituted in 0.1% formic acid prior to nanoflow reversed-phase liquid chromatography (nanoRPLC) mass spectrometry analysis. NanoRPLC columns were slurry packed with 5 μm, 300 Å pore size C-18 silica-bonded stationary reverse-phase particles (Jupiter; Phenomenex, Torrance, CA, USA) in a 75 μm internal diameter × 10 cm fused silica capillary with a flame pulled tip. The column was connected to an Agilent 1100 nanoLC system and coupled to a linear ion trap (LIT) mass spectrometer (LTQ, ThermoElectron, , San Jose, CA, USA, operated with Xcalibur 1.4 SR1 software). The samples were injected onto the column and the peptides eluted using a gradient of mobile phase A (0.1% formic acid in water) and B (0.1% formic acid in acetonitrile). The LTQ was operated in a data-dependent mode in which the seven most abundant peptide molecular ions in every MS scan were sequentially selected for collision-induced dissociation (CID) using a normalized collision energy of 35%. Dynamic exclusion was applied to minimize repeated selection of peptides previously selected for CID.
Tandem mass spectra were searched against the UniProt human proteomic database from the European Bioinformatics Institute with SEQUEST (http://fields.scripps.edu/sequest/) operating on a 40-node Beowulf cluster. Peptides were searched using fully tryptic cleavage constraints. Oxidation of methionine (+15.9949 Da) was included as dynamic modification. For a peptide to be considered legitimately identified, it must have achieved a minimum Δ correlation (ΔCn) of 0.08 and charge state-dependent cross correlation (Xcorr) scores of 1.9 for [M + H]1+, 2.2 for [M + 2H]2+, and 3.1 for [M + 3H]3+ peptide molecular ions. Data were subjected to functional analysis through the use of Ingenuity pathways analysis (IPA; Ingenuity Systems, http://​www.​ingenuity.​com) and BIOBASE (http://​www.​biobase-international.​com).

Estrogen metabolite analysis

Reagents and materials for steroid analysis

A total of 15 estrogens including estrone (E1), estradiol (E2), estriol (E3), 16-epiestriol (16-epiE3), 17-epiestriol (17-epiE3), 16-ketoestradiol (16-ketoE2), 16α-hydroxyestrone (16α-OHE1), 2-methoxyestrone (2-MeOE1), 4-methoxyestrone (4-MeOE1), 2-hydroxyestrone-3-methyl ether (3-MeOE1), 2-methoxyestradiol (2-MeOE2), 4-methoxyestradiol (4-MeOE2), 2-hydroxyestrone (2-OHE1), 4-hydroxyestrone (4-OHE1), and 2-hydroxyestradiol (2-OHE2) and 2 androgens, androstenedione and testosterone, were obtained from Steraloids (Newport, RI, USA). Stable isotope labeled steroids, including estradiol-13,14,15,16,17,18-13C6 (13C6-E2) and estrone-13,14,15,16,17,18-13C6 (13C6-E1) were purchased from Cambridge Isotope Laboratories (Andover, MA, USA); estriol-2,4,17-d 3 (d3-E3), 2-hydroxyestradiol-1,4,16,16,17-d 5 (d5-2-OHE2), 2-methoxyestradiol-1,4,16,16,17-d 5 (d5-2-MeOE2), androstenedione-2,2,4,6,6,16,16-d 7 and testosterone-16,16,17-d 3 were obtained from C/D/N Isotopes (Pointe-Claire, Quebec, Canada). 16-Epiestriol-2,4,16-d 3 (d3-16-epiE3) was purchased from Medical Isotopes (Pelham, NH, USA). All steroid analytical standards have reported chemical and isotopic purity ≥98%, and were used without further purification. Dichloromethane and methanol were obtained from EM Science (Gibbstown, NJ, USA). Glacial acetic acid and sodium bicarbonate were purchased from JT Baker (Phillipsburg, NJ, USA) and sodium hydroxide and sodium acetate were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Ethyl alcohol was obtained from Pharmco Products (Brookfield, CT, USA). Formic acid, acetone, dansyl chloride, and L-ascorbic acid were obtained from Sigma-Aldrich (St Louis, MO, USA). All chemicals and solvents used in this study were high performance liquid chromatography (HPLC) or reagent grade unless otherwise noted.

Preparation of stock and working standard solutions

Stock solutions of steroids and stable isotope labeled steroids were each prepared at 80 μg/ml by dissolving 2 mg of each estrogen powder in methanol containing 0.1% l-ascorbic acid to a final volume of 25 ml in a volumetric flask. Stock solutions were monitored by measuring the absolute peak height of each steroid using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) to verify that no time-dependent degradation of steroid standards had occurred. The stock solutions are stable for at least 2 months while stored at -20°C. Working standard solutions of steroids at 0.32 and 8.0 ng/ml were prepared by dilutions of the stock solutions with methanol containing 0.1% l-ascorbic acid.

Sample preparation procedure

To quantitatively measure unconjugated biologically active estrogen metabolites (EM) and androgens, breast tissue samples (0.2-0.3 g per patient) were thawed briefly at room temperature, minced with scissors, and transferred into 1.5 ml Eppendorf tubes. A total of 19 AA patient samples and 20 CAU samples were analyzed. The tissue was hardened by snap freezing in liquid nitrogen for 5 min, pulverized and then transferred into a clean screw-capped glass tube containing 1 ml of ice-cold 12.5 mM NH4HCO3 buffer. The tissue was homogenized on ice using a Tissue Tearor (Cole-Parmer, Vernon Hills, IL, USA) at low and high speed in two consecutive 15 s segments for a total of 30 s, and further sonicated on ice for five cycles of 10 s pulses with 10 s breaks in between pulses. Then, 8 ml of ethanol:acetone and 50 μl each of stable isotope-labeled estrogen and androgen internal standards (0.32 ng/ml working standard solutions) were added to each tissue homogenate. The mixture was incubated on a rotator at room temperature for 1 h and centrifuged at 3,000 g for 30 min. The ethanol:acetone tissue extract was transferred to a clean glass tube and dried under nitrogen gas at 60°C for 1 h (Reacti-Vap III, Pierce, Rockford, IL, USA). The residue was redissolved in 4 ml of methanol, vortexed for 1 min, chilled at -80°C for 1 h, returned to room temperature and then centrifuged at 3,000 g for 20 min. The methanolic phase was transferred to a clean glass tube and dried under nitrogen gas. The residue was further redissolved in 100 μl of ethanol and vortexed briefly. This was followed by the addition of 1.5 ml of 100 mM sodium acetate buffer, pH 4.6 and 5 ml of dichloromethane to the residue, and incubation at room temperature on a rotator for 30 min. The extract was chilled at -80°C for 10 min, returned to room temperature and centrifuged at 3,000 g for 20 min. The dichloromethane phase was transferred to a clean tube and dried. To each dried sample, 32 μl of 0.1 M sodium bicarbonate buffer, pH 9.0, and 32 μl of dansyl chloride solution (1 mg/ml in acetone) were added. After vortexing for 10 s, samples were heated at 70°C (Reacti-Therm III Heating Module; Pierce) for 10 min to form the EM and d-EM dansyl derivatives. The dansyl derivatization method modifies the phenol hydroxyl group of EM and will not react with testosterone. After derivatization, all samples were centrifuged at 3,000 g for 20 min, and analyzed by the capillary LC-ESI-MS/MS.

Capillary liquid chromatography-electrospray ionization tandem mass spectrometry analysis (Cap LC-ESI-MS/MS)

Capillary LC-ESI-MS/MS analysis was performed using an Agilent 1200 series nanoflow LC system (Agilent Technologies, Palo Alto, CA, USA) coupled to a TSQ Quantum Ultra triple quadrupole mass spectrometer (ThermoElectron). The LC separation was carried out on a 150 mm long × 300 μm internal diameter column packed with 4 μm Synergi Hydro-RP particles (Phenomenex) and maintained at 40°C. A total of 8.0 μl of each sample was injected onto the column. The mobile phase, operating at a flow rate of 4.0 μl/min, consisted of methanol as solvent A and 0.1% (v/v) formic acid in water as solvent B. A linear gradient increasing from 72% to 85% solvent A in 75 min was employed for the separation. The MS conditions were source: ESI; ion polarity: positive; spray voltage: 3,500 V; sheath and auxiliary gas: nitrogen; sheath gas pressure: 7 arbitrary units; ion transfer capillary temperature, 270°C; scan type: selected reaction monitoring (SRM); collision gas: argon; collision gas pressure: 1.5 mTorr; scan width: 0.7 u; scan time: 0.50 s; Q1 peak width: 0.70 u full-width half-maximum (FWHM); Q3 peak width: 0.70 u FWHM. The specific SRM transitions of protonated androgens were: testosterone m/z 289→97 and 109; testosterone-d 3 m/z 292→97 and 109; androstenedione m/z 287→97 and 109; androstenedione-d 7 m/z 287→100 and 113.

Quantitation of tissue estrogens and androgens

Quantitation of tissue estrogens and androgens was carried out using Xcalibur Quan Browser (ThermoElectron). Briefly, calibration curves for each steroid were constructed by plotting non-labeled steroid/stable isotope labeled steroid peak area ratios obtained from calibration standards versus amounts of the steroid injected on the column and fitting these data using linear regression with 1/X weighting. The amounts of steroid in the tissue were then interpolated using this linear function.

Statistical analysis

Pools of patient samples were necessary to obtain the required amount of tissue for ECM extraction. When appropriate, data was evaluated for significance via two-tailed Student t tests, repeated measures analysis of variance (ANOVA) with the Bonferroni multiple comparisons post hoc analysis, Wilcoxon matched pairs, or Mann-Whitney tests using GraphPad InStat Software version 3.0b (San Diego, CA, USA). Data was considered significant at P < 0.05.

Results

Effects of premenopausal breast fibroblasts on breast cancer cell tumorigenicity

It has previously been shown that tumor-derived fibroblasts promote, while normal fibroblasts inhibit, the growth of tumorigenic epithelial cells in vitro and in vivo [7, 27]. Therefore, we first 'humanized' the mouse mammary gland [27] creating a microenvironment with supportive stromal components from either the AA or CAU breast. Primary breast fibroblasts from age-matched, premenopausal women were isolated [22] and a pool of a minimum of three patient-derived fibroblasts per group was injected into mouse abdominal mammary glands. A different pool of patient fibroblasts was used for each of three independent humanization experiments. As shown in Figure 1a, both the AA and CAU fibroblasts equally humanized the glands, suggesting that the source of the fibroblasts did not have an effect on the percentage of growth throughout the glands.
Following humanization, primary metastatic breast cancer cells (ER-/PR-, as described in Methods) were injected into the glands. Injection of breast cancer cells into the humanized glands was repeated in two independent experiments using different pools of patient-derived normal breast fibroblasts; however, the same breast cancer patient sample was used specifically to minimize any confounding effects of the relatively uncharacterized primary breast cancer cells. For all treatments tested, the tumor incidence was 100%, with no obvious morphological differences between treatment groups; tumors were ER-/PR-, undifferentiated invasive carcinomas. Interestingly, glands humanized with CAU fibroblasts repeatedly developed significantly larger tumors compared to AA humanized glands (Figure 1b, P < 0.008) suggesting that either CAU fibroblasts were more permissive to tumorigenesis, or that AA fibroblasts were more restrictive. There was no significant difference in the Ki67 proliferation index at the time of tumor collection (Additional file 1, Figure S1a). Additionally, of the tumors that contained necrotic regions, there was no significant difference in the percentage of necrotic area; however, it should be noted that the significantly larger tumors from glands humanized with CAU fibroblasts had overall higher levels of tumors containing necrotic regions compared to the AA humanized glands (50% vs 33%, Additional file 1, Figure S1b).
A similar pattern of tumor formation was observed using T47D, a well characterized, ER+/PR+ human breast cancer cell line; the cells injected into the glands humanized with the CAU fibroblasts had increased tumor volume (Figure 1c, P < 0.05). The resultant tumors from both treatment groups were ER+/PR+ by immunohistochemistry (data not shown); therefore the hormonal status of the cells was retained regardless of the source of fibroblasts.
In the presence of fibroblasts derived from the two groups, differences in tumorigenicity were observed. Therefore, the expression profiles of 164 ECM molecules and cytokines were examined using qRT-PCR arrays. Cytokines were analyzed since components of the immune system have been reported to modulate the initiation and progression of breast cancer, including metastasis to bone [2832]. Fibroblasts were expanded in culture for less than two passages prior to isolation of total RNA. Different pools of at least three patient samples per group were used in each of three independent array experiments (n = 9 AA, n = 10 CAU). A set of ECM proteins and cytokines was consistently differentially regulated between the two groups (Additional file 1, Figure S2a and b, respectively). Array results were validated by qRT-PCR; expression patterns were observed not only using samples from the array analysis, but also with additional randomly chosen, freshly isolated, individual patient samples (n = 18, Figure 1d, e). As expected, there was substantial individual patient variation; however, 13 of the 18 genes that were differentially expressed between the groups in the array analysis were significantly different when individual patient samples were analyzed (P < 0.05). Of note, CAU-derived fibroblasts repeatedly exhibited an increase in cytokine expression (Figure 1e and Additional file 1, Figure S2b). This observation may explain, in part, the increase in tumor growth observed in the xenograft experiments (Figure 1b, c). Collectively, these data suggest that when stromal fibroblasts are confronted with the invasion of tumorigenic breast cells, genetic variation between the groups differentially affected tumorigenesis via the production of distinctive ECM molecules and cytokines.

Effects of premenopausal breast ECM on breast cancer cells in vitro

Numerous cell types, in addition to fibroblasts, comprise the breast microenvironment. To gain further insight into these multicellular interactions, we analyzed a broader spectrum of molecules within the breast by isolating ECM proteins from premenopausal whole breast tissue. In order to test whether ECM isolated from whole breast tissue was able to differentially influence breast cancer cell aggressiveness, we examined cell motility and invasiveness using transwell filter assays. Two classes of breast cancer cell lines were used: ER-/PR- (MDA-MB-231, SUM159, MCF10Ca1h) and ER+/PR+ (T47D, MCF7, BT474). These cell lines were chosen for their well characterized phenotype, specifically to limit any confounding effects of uncharacterized primary breast cancer cells. Cells were overlaid onto one of the three matrices (adjusted for equal protein concentration) and allowed to respond to a chemoattractant. Four independent experiments, each with different pools of patient samples (minimum of three patient samples per pool), were performed with each individual experiment repeated in duplicate to ensure repeatability. Cell invasion through the control matrix was low for all cell lines tested (Figure 2a). Interestingly, the ability of cells to invade through the ECM was dependent upon both the cell's hormone receptor status and the source of the ECM. The ER-/PR- cells were consistently more invasive when in contact with the AA ECM. Conversely, all of the ER+/PR+ cell lines tested were more invasive when in contact with the CAU ECM, suggesting that the invasiveness of cells was enhanced by a hormone receptor-dependent mechanism in the presence of CAU ECM. The increased invasiveness may have occurred through a combinatorial effect of ECM components and hormones in the chemoattractant serum. This potential hormone receptor-dependent stimulus had no effect on the ER-/PR- cells. In the AA-derived ECM, however, a hormone-independent mechanism appeared to further stimulate the invasiveness of the ER-/PR- cells.
Soft agar transformation assays were performed to measure whether the addition of either ECM could differentially influence cell survival under anchorage-independent conditions, mimicking changes that occur during tumorigenesis. Results were similar to those observed with invasion assays; the AA ECM significantly increased the number of colonies for the ER-/PR- MDA-MB-231 cells above all other treatments (P < 0.01, Figure 2b). Similar results were observed with SUM159 and MCF10Ca1h cells (Additional file 1, Figure S3). Additionally, the CAU ECM significantly increased colony formation above untreated controls for the ER+/PR+ T47D cell line (P < 0.05 Figure 2b, similarly for MCF7, ZR75-1, and BT474 cells; Additional file 1, Figure S3). Thus, the ability of the cells to survive and proliferate in hostile, anchorage-independent conditions appeared dependent upon both the source of the ECM and the hormonal status of the cells.
To further analyze the composition of the whole breast ECM, we assessed its protease activity. The stroma can act as a reservoir for matrix metalloproteinases (MMPs), which degrade ECM proteins and process a number of bioactive molecules. In breast tissue, MMP activity contributes to epithelial cell death, influences tissue remodeling, and has been implicated in cancer invasion and metastasis [3335]. Gelatin zymography was employed, and in multiple experiments the protease activity of at least two different MMPs was upregulated in the CAU compared to the AA ECM as determined using gelatin zymography (representative gel; Figure 2c). When compared to the fibroblast PCR array analysis, there was no significant increase in MMP expression in the CAU fibroblasts compared to the AA, indicating that cells other than fibroblasts produce MMPs, or that there is increased stimulation of MMP activity in CAU versus AA ECM.

Effects of ECM on tumorigenicity in vivo

We sought to address whether factors within the breast ECM, removed from the physical presence of stromal cells, could affect the tumorigenicity of breast cancer cells in vivo. As described by McDaniel et al. [26], ER-/PR- MDA-MB-231 or ER+/PR+ T47D breast cancer cells were mixed with control matrix (Matrigel), AA or CAU ECM (adjusted for equal protein content) and injected into the abdominal mammary fat pad of female, athymic nude mice. No significant difference in tumor efficiency was observed among the treatments (Figure 3a). However, the CAU ECM significantly increased tumor growth of the ER+/PR+ T47D cells compared to either the AA ECM or control matrix control (Figure 3b; P < 0.01 and 0.05, respectively). AA ECM elicited no difference in growth compared to the control matrix. The resultant T47D tumors from all treatment groups were ER+; confirming that hormone status of the cells was retained during tumor formation (data not shown). Tumor morphology and percentage necrosis were similar between treatments. These data support the observation that factors within CAU ECM selectively interact with ER+/PR+ cells to increase their aggressiveness. The in vitro data demonstrating enhanced MMP activity and increased cytokine production in the CAU microenvironment could potentially account for this increase in tumor growth.
Conversely, injecting ER-/PR- MDA-MB-231 cells with ECM derived from either group gave no selective advantage in tumor growth. Only cells injected with growth factor-rich control matrix had significantly increased final tumor volume (P < 0.05, Figure 3c). To confirm that the ECM's effect on tumorigenicity was not masked due to interactions with the host mammary gland, MDA-MD-231 cells were mixed with control matrix, AA or CAU ECM, adjusted for equal protein content, and injected subcutaneously into athymic nude mice. A similar trend to results obtained from the orthotopic site was observed. Only cells injected with the control matrix had substantially larger final tumor volume compared to cells injected with ECM derived from either group, although no statistically significant difference was observed between either ECM (Figure 3d). No significant difference in tumor latency was observed among the treatments.
Metastasis to the lung and liver was low for all treatments and cell lines tested. Of the 75 lung samples analyzed, only 18 tested positive for lung metastasis via pathological examination, immunohistochemical analysis for human specific COXIV, and qRT-PCR for human β2-microglobin [26] (Figure 4). No liver metastases were found by histological examination. Regardless of the cell type injected, the CAU ECM elicited at least twice the metastases as AA ECM (Figure 4a). Figure 4c depicts representative images of hematoxylin and eosin (H&E)-stained lungs with overt metastases resulting from the two cell types, and metastatic cells within the lung were detected by a human specific COXIV antibody (Figure 4d). No correlation between the size of the primary tumor and metastasis and no significant difference between the amount of metastasis and treatment was observed for all samples analyzed.

Mass spectrometry analysis of the ECM

To determine whether the overall composition of the ECM differed between premenopausal AAs and CAUs, breast ECM proteins were intimately examined by LC-MS/MS. Three independent ECM extraction experiments, using different patient samples for each experiment, with at least three patients per group, (that is, a total of six individual ECM pools) were analyzed using LC-MS/MS. Among the 4,288 AA and 4,301 CAU proteins identified, only 1,759 were common between the groups. Ingenuity pathways analysis (IPA, Ingenuity Systems, http://​www.​ingenuity.​com) was used for functional analysis of the results. The majority of the high abundance proteins (≥30 peptide matches) consisted of structural ECM proteins including numerous collagen species. These were comparatively similar for either group. Therefore, we excluded those identified by ≥30 peptides to focus on those with lower abundance. Additionally, although it is possible to identify a protein from a single peptide match after careful inspection of the fragment's pattern and other characteristics, we excluded these single unique peptides and focused our studies on those above two peptide matches. During analysis, proteins reported to be exclusively nuclear were excluded as cellular contamination (23.4% for the AA dataset and 23.0% for the CAU dataset). In addition to ECM structural proteins, another distinct feature of the microenvironment is the presence of extracellular matrix vesicles (MV) and exosomes, small sacs secreted from the cell surface which are enclosed by a membrane structurally similar to that of the plasma membrane [36]. Molecules located within MV/exosomes perform diverse functions outside of the cell including growth factor storage and secretion, immune regulation, ECM mineralization, and RNA shuttling. Interestingly, tumor-associated MV/exosomes have been shown to contribute to the ability of tumor cells to escape immune surveillance, degrade ECM to facilitate invasion, and stimulate angiogenesis [36]. Therefore, no cytosolic proteins that may have been released into the ECM by MV/exosomes were excluded. Representative western blot images of four randomly chosen proteins were selected for validation of LC-MS/MS analysis with their corresponding numbers of peptides identified (Figure 5a, representative spectra shown in Additional file 1, Figure S4).
Pathways analyses by IPA revealed that the actin cytoskeleton signaling and the hepatic fibrosis/hepatic stellate cell activation pathways were only significant for the AA dataset, based on a strict P value threshold of 0.005 and Benjamini-Hochberg correction (Figure 5b). Both of these pathways, as well as tight junction signaling and regulation of actin-based motility by Rho, had numerous molecules in common including Rho-associated kinase (ROCK), actin, and several myosins. The significant presence of these pathways in only the AA microenvironment implies unique cytoskeletal signaling compared to that in CAU.
To further examine differences among datasets, we analyzed networks created by proteins found exclusively in the AA or the CAU datasets. The network with the highest score for the AA dataset contained seven nodes representing proteins/genes associated with tight junction signaling and actin cytoskeleton signaling pathway (Figure 5c). The top network generated by the CAU dataset contained several other adhesion molecules and the epidermal growth factor receptor ErbB3, which is known to promote epithelial cell growth and antiapoptotic signaling. ErbB3 is often overexpressed in human breast cancers, frequently in conjunction with overexpression of the proto-oncogene ErbB2/HER2 [37]. Interestingly, the CAU dataset also contained molecules associated with the Wnt/β-catenin pathway (Figure 5c), whose dysregulation has been implicated in breast cancer development and progression [38]. Additional networks for the AA can CAU datasets can be found in Additional file 1, Figures S5a-d and S6a-d.
Based on annotations by two manually curated databases (IPA and BIOBASE, http://​www.​biobase-international.​com), similar and unique proteins to each dataset, and their known associations with breast cancer, were examined. The AA and CAU datasets had 52 common molecules (Table 1) and 48 and 47 unique proteins, respectively (Tables 2 and 3). Further functional analyses of these proteins indicated that the AA dataset were mainly related to initiation events, including tumorigenesis and neoplasia. Alternatively, the proteins unique to the CAU dataset were primarily involved with tumor growth or metastasis.
Table 1
Proteins found in both African-American and Caucasian-American datasets reported to be involved in breast cancer, as annotated by Ingenuity Systems or BIOBASE.
Symbol
Entrez gene name
Location
Entrez gene ID
ABCC4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4
Plasma membrane
10257
ACTA2
Actin, alpha 2, smooth muscle, aorta
Cytoplasm
59
ACTB
Actin, beta
Cytoplasm
60
ADAMTS15
ADAM metallopeptidase with thrombospondin type 1 motif, 15
Extracellular space
170689
ADRA1B
Adrenergic, alpha-1B-, receptor
Plasma membrane
147
ANXA2
Annexin A2
Plasma membrane
302
APOB
Apolipoprotein B (including Ag(x) antigen)
Extracellular space
338
APOD
Apolipoprotein D
Extracellular space
347
ATP5B
ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide
Cytoplasm
506
AXL
AXL receptor tyrosine kinase
Plasma membrane
558
C3
Complement component 3
Extracellular space
718
CAV1
Caveolin 1, caveolae protein, 22 kDa
Plasma membrane
857
CNR2
Cannabinoid receptor 2 (macrophage)
Plasma membrane
1269
COL18A1
Collagen, type XVIII, alpha 1
Extracellular space
80781
CYP2C9
Cytochrome P450, family 2, subfamily C, polypeptide 9
Cytoplasm
1559
DCD
Dermcidin
Extracellular space
117159
DSP
Desmoplakin
Plasma membrane
1832
FES
Feline sarcoma oncogene
Cytoplasm
2242
FN1
Fibronectin 1
Plasma membrane
2335
GART
Phosphoribosylglycinamide formyltransferase/synthetase,
Cytoplasm
2618
GFRA1
GDNF family receptor alpha 1
Plasma membrane
2674
HSPA5
Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa)
Cytoplasm
3309
HSPG2
Heparan sulfate proteoglycan 2
Plasma membrane
3339
IGF2R
Insulin-like growth factor 2 receptor
Plasma membrane
3482
IGKC
Immunoglobulin kappa constant
Extracellular space
3514
ITGA2
Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
Plasma membrane
3673
JUP
Junction plakoglobin
Plasma membrane
3728
LAMA3
Laminin, alpha 3
Extracellular space
3909
LDHA
Lactate dehydrogenase A
Cytoplasm
3939
LEPR
Leptin receptor
Plasma membrane
3953
LGALS1
Lectin, galactoside-binding, soluble, 1
Extracellular space
3956
MAGED1
Melanoma antigen family D, 1
Plasma membrane
9500
MAP3K4
Mitogen-activated protein kinase kinase kinase 4
Cytoplasm
4216
MUC16
Mucin 16, cell surface associated
Extracellular space
94025
MUC5AC
Mucin 5AC, oligomeric mucus/gel-forming
Extracellular space
4586
NF1
Neurofibromin 1
Cytoplasm
4763
PCM1
Pericentriolar material 1
Cytoplasm
5108
POSTN
Periostin, osteoblast specific factor
Extracellular space
10631
PRDX3
Peroxiredoxin 3
Cytoplasm
10935
PRKCG
Protein kinase C, gamma
Cytoplasm
5582
PRLR
Prolactin receptor
Plasma membrane
5618
PTN
Pleiotrophin
Extracellular space
5764
PTPN13
Protein tyrosine phosphatase, non-receptor type 13
Cytoplasm
5783
PXDN
Peroxidasin homolog (Drosophila)
Unknown
7837
SERPINA1
Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin) 1
Extracellular space
5265
SLC16A3
Solute carrier family 16, member 3 (monocarboxylic acid transporter 4)
Plasma membrane
9123
SLC19A1
Solute carrier family 19 (folate transporter), member 1
Plasma membrane
6573
TES
Testis derived transcript (3 LIM domains)
Plasma membrane
26136
TNC
Tenascin C
Extracellular space
3371
TUBA1A
Tubulin, alpha 1a
Cytoplasm
7846
VCL
Vinculin
Plasma membrane
7414
VTN
Vitronectin
Extracellular space
7448
Table 2
Proteins found unique to the African-American dataset that are reported to be involved in breast cancer, as annotated by Ingenuity Systems or BIOBASE.
Symbol
Entrez gene name
Location
Entrez gene ID
ADAM12
ADAM metallopeptidase domain 12
Plasma membrane
8038
ADRA2C
Adrene gic, alpha-2C-, receptor
Plasma membrane
152
AKR1C1
Aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1)
Cytoplasm
1645
ANK1
Ankyrin 1, erythrocytic
Plasma membrane
286
ANXA1
Annexin A1
Plasma membrane
301
ANXA5
Annexin A5
Plasma membrane
308
BCAS1
Breast carcinoma amplified sequence 1
Unknown
8537
CAMKK1
Calcium/calmodulin-dependent protein kinase kinase 1, alpha
Cytoplasm
84254
CANX
Calnexin
Cytoplasm
821
CASP1
Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, convertase
Cytoplasm
834
CD69
CD69 molecule
Plasma membrane
969
CDH11
Cadherin 11, type 2, OB-cadherin (osteoblast)
Plasma membrane
1009
CDR2
Cerebellar degeneration-related protein 2, 62 kDa
Cytoplasm
1039
CTSD
Cathepsin D
Cytoplasm
1509
DAB2
Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)
Plasma membrane
1601
DECR1
2,4-Dienoyl CoA reductase 1, mitochondrial
Cytoplasm
1666
DFNA5
Deafness, autosomal dominant 5
Unknown
1687
DLC1
Deleted in liver cancer 1
Cytoplasm
10395
EDNRB
Endothelin receptor type B
Plasma membrane
1910
EEF1A1
Eukaryotic translation elongation factor 1 alpha 1
Cytoplasm
1915
ERBB4
V-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)
Plasma membrane
2066
FBLN1
Fibulin 1
Extracellular space
2192
GAPDH
Glyceraldehyde-3-phosphate dehydrogenase
Cytoplasm
2597
GRIN2D
Glutamate receptor, ionotropic, N-methyl d-aspartate 2D
Plasma membrane
2906
GSN
Gelsolin (amyloidosis, Finnish type)
Extracellular space
2934
HSPB1
Heat shock 27 kDa protein 1
Cytoplasm
3315
IGF1R
Insulin-like growth factor 1 receptor
Plasma membrane
3480
KDR
Kinase insert domain receptor (a type III receptor tyrosine kinase)
Plasma membrane
3791
LTF
Lactotransferrin
Extracellular space
4057
MET
Met proto-oncogene (hepatocyte growth factor receptor)
Plasma membrane
4233
MMP14
Matrix metallopeptidase 14 (membrane-inserted)
Extracellular space
4323
MUC6
Mucin 6, oligomeric mucus/gel-forming
Extracellular space
4588
NLRP1
NLR family, pyrin domain containing 1
Cytoplasm
22861
ORM1
Orosomucoid 1
Extracellular space
5004
PDGFRB
Platelet-derived growth factor receptor, beta polypeptide
Plasma membrane
5159
PLXNA1
Plexin A1
Plasma membrane
5361
POR
P450 (cytochrome) oxidoreductase
Cytoplasm
5447
PTPRG
Protein tyrosine phosphatase, receptor type, G
Plasma membrane
5793
ROCK1
Rho-associated, coiled-coil containing protein kinase 1
Cytoplasm
6093
S100A9
S100 calcium binding protein A9
Cytoplasm
6280
SERPINA3
Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase), member 3
Extracellular space
12
SERPINB5
Serpin peptidase inhibitor, clade B (ovalbumin), member 5
Extracellular space
5268
SOD1
Superoxide dismutase 1, soluble
Cytoplasm
6647
SOD2
Superoxide dismutase 2, mitochondrial
Cytoplasm
6648
SYK
Spleen tyrosine kinase
Cytoplasm
6850
TAGLN
Transgelin
Cytoplasm
6876
TJP1
Tight junction protein 1 (zona occludens 1)
Plasma membrane
7082
TXNRD1
Thioredoxin reductase 1
Cytoplasm
7296
Table 3
Proteins found unique to the Caucasian-American dataset that are reported to be involved in breast cancer, as annotated by Ingenuity Systems or BIOBASE.
Symbol
Entrez gene name
Location
Entrez gene ID
ABCC5
ATP-binding cassette, sub-family C (CFTR/MRP), member 5
Plasma membrane
10057
ACE
Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
Plasma membrane
1636
BCAR3
Breast cancer anti-estrogen resistance 3
Cytoplasm
8412
CDON
Cdon homolog (mouse)
Plasma membrane
50937
CLCA2
CLCA family member 2, chloride channel regulator
Plasma membrane
9635
CSF1R
Colony stimulating factor 1 receptor
Plasma membrane
1436
CTGF
Connective tissue growth factor
Extracellular space
1490
DAPK1
Death-associated protein kinase 1
Cytoplasm
1612
DLG5
Discs, large homolog 5 (Drosophila)
Plasma membrane
9231
ERBB3
V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
Plasma membrane
2065
FRZB
Frizzled-related protein
Extracellular space
2487
GREB1
GREB1 protein
Cytoplasm
9687
HGF
Hepatocyte growth factor (hepapoietin A; scatter factor)
Extracellular space
3082
HPN
Hepsin (transmembrane protease, serine 1)
Plasma membrane
3249
HSPA8
Heat shock 70 kDa protein 8
Cytoplasm
3312
IL17RB
Interleukin 17 receptor B
Plasma membrane
55540
IRS2
Insulin receptor substrate 2
Cytoplasm
8660
ITGA6
Integrin, alpha 6
Plasma membrane
3655
KCNH1
Potassium voltage-gated channel, subfamily H (eag-related), member 1
Plasma membrane
3756
KISS1
KiSS-1 metastasis-suppressor
Cytoplasm
3814
LGALS3
Lectin, galactoside-binding, soluble, 3
Extracellular space
3958
LPA
Lipoprotein, Lp(a)
Extracellular space
4018
LPHN2
Latrophilin 2
Plasma membrane
23266
LTA
Lymphotoxin alpha (TNF superfamily, member 1)
Extracellular space
4049
MAP2K5
Mitogen-activated protein kinase kinase 5
Cytoplasm
5607
MINK1
Misshapen-like kinase 1 (zebrafish)
Cytoplasm
50488
NOS3
Nitric oxide synthase 3 (endothelial cell)
Cytoplasm
4846
NOTCH4
Notch homolog 4 (Drosophila)
Plasma membrane
4855
NRG1
Neuregulin 1
Extracellular space
3084
OAS3
2'-5'-oligoadenylate synthetase 3, 100 kDa
Cytoplasm
4940
P4HB
Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide
Cytoplasm
5034
PKD1
Polycystic kidney disease 1 (autosomal dominant)
Plasma membrane
5310
PLG
Plasminogen
Extracellular space
5340
PTPRF
Protein tyrosine phosphatase, receptor type, F
Plasma membrane
5792
RASA1
RAS p21 protein activator (GTPase activating protein) 1
Cytoplasm
5921
SERPINI2
Serpin peptidase inhibitor, clade I (pancpin), member 2
Extracellular space
5276
SH3RF1
SH3 domain containing ring finger 1
Cytoplasm
57630
SOCS1
Suppressor of cytokine signaling 1
Cytoplasm
8651
TBC1D9
TBC1 domain family, member 9 (with GRAM domain)
Plasma membrane
23158
TGFBR2
Transforming growth factor, beta receptor II (70/80 kDa)
Plasma membrane
7048
TIAM1
T-cell lymphoma invasion and metastasis 1
Cytoplasm
7074
TNN
Tenascin N
Plasma membrane
63923
TPI1
Triosephosphate isomerase 1
Cytoplasm
7167
VWF
von Willebrand factor
Extracellular space
7450
WISP2
WNT1 inducible signaling pathway protein 2
Extracellular space
8839
WNT11
Wingless-type MMTV integration site family, member 11
Extracellular space
7481
YWHAZ
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide
Cytoplasm
7534

Biologically active estrogen and androgen metabolites

In this study, we show that CAU-derived ECM enhanced the aggressiveness of ER+/PR+ breast cancer cells, suggesting the microenvironment from which the ECM was derived may have been exposed to a different hormonal milieu compared to the AA. Therefore, the hormones present in the breast microenvironment were quantitatively measured by a novel method of LC-MS/MS that simultaneously extracted and analyzed biologically active estrogen and androgen metabolites present in whole tissue samples. Breast tissues from fasting, premenopausal AA and CAU women (median age 32 and 31, respectively; n = 19 AA and 20 CAU) were analyzed. Both androstenedione and testosterone were detected in all tissues (Figure 6a, Table 4). Testosterone appeared elevated in the AA breast tissue; however, this observation was not statistically significant. It is of note that androgens levels were significantly higher in breast tissue compared to estrogens (P < 0.001, Tables 4 and 5), similar to what has been repeatedly observed in blood. More importantly, these results shows that the unconjugated biologically active estrogens found in premenopausal breast tissues were higher than those reported in blood [39]. These results warrant further study given the role of estrogen metabolites in tumorigenesis.
Table 4
Unconjugated biologically active androgens (pg/g) detected in breast tissue.
Sample ID
Wet weight (g)
Androstenedione
Testosterone
Total
AA1
0.307
2,546.9
428.5
2,975.4
AA2
0.293
2,393.9
422.5
2,816.4
AA3
0.305
673.7
20,433.2
21,106.9
AA4
0.290
2,922.5
628.7
3,551.2
AA6
0.375
1,196.0
419.9
1,615.9
AA7
0.317
6,634.4
872.9
7,507.3
AA8
0.324
443.1
152.6
595.7
AA10
0.272
2,748.0
470.5
3,218.6
AA11
0.249
844.5
224.6
1,069.2
AA12
0.270
1,099.8
184.6
1,284.4
AA13
0.269
601.8
120.1
721.9
AA14
0.289
2,890.2
373.8
3,264.0
AA15
0.299
4,678.6
664.0
5,342.6
AA16
0.345
832.0
184.3
1,016.3
AA17
0.298
1,314.9
203.8
1,518.7
AA18
0.299
562.4
667.5
1,229.9
AA19
0.263
910.0
184.4
1,094.4
AA5
0.348
1,588.9
227.4
1,816.3
Mean
0.303
1,937.9
1,492.4
3,430.3
SD
0.033
1,634.7
4,731.9
4,756.7
SEM
0.008
385.3
1,115.3
1,121.2
CA1
0.267
5,927.3
1,103.9
7,031.2
CA2
0.283
1,904.7
178.2
2,082.9
CA3
0.268
2,390.2
424.8
2,815.0
CA4
0.328
311.5
141.4
452.9
CA5
0.260
879.7
740.8
1,620.5
CA6
0.294
962.5
211.5
1,173.9
CA7
0.295
1,425.8
155.2
1,581.0
CA8
0.260
515.2
180.6
695.8
CA9
0.255
1,993.1
536.8
2,529.9
CA10
0.324
710.3
588.4
1,298.7
CA12
0.305
1,448.6
284.1
1,732.7
CA14
0.208
1,540.4
361.3
1,901.8
CA15
0.258
2,997.8
437.5
3,435.3
CA16
0.319
1,068.2
4,855.9
5,924.1
CA17
0.310
1,062.6
295.0
1,357.6
CA18
0.297
3,515.1
343.6
3,858.7
CA19
0.323
3,906.8
165.4
4,072.2
CA20
0.312
3,070.7
95.9
3,166.6
Mean
0.29
1,979.47
616.69
2,596.16
SD
0.03
1,440.86
1,087.75
1,757.64
SEM
0.01
339.61
256.38
414.28
SEM = standard error of the mean.
Table 5
Unconjugated biologically active estrogens (pg/g) detected in breast tissue.
Sample ID
Wet weight (g)
16KE2
E3
16aE1
16epiE3
17epiE3
3ME1
2ME1
4ME1
2ME2
E1
4ME2
E2
2OHE1
2OHE2
4OHE1
Total (pg/g)
AA1
0.307
ND
3.92
ND
ND
ND
ND
24.34
ND
ND
459.21
ND
138.15
ND
ND
ND
625.63
AA2
0.293
ND
6.86
ND
ND
ND
ND
4.21
ND
ND
456.38
ND
210.90
ND
21.41
ND
699.77
AA3
0.305
ND
6.44
ND
ND
ND
ND
4.33
ND
ND
26.35
ND
15.42
ND
ND
ND
52.55
AA4
0.290
ND
7.33
ND
ND
ND
ND
4.23
ND
ND
314.41
ND
105.14
ND
14.77
ND
445.87
AA5
0.348
ND
24.88
ND
ND
ND
ND
16.47
ND
ND
313.31
ND
69.34
ND
ND
ND
424.00
AA6
0.375
ND
18.97
ND
ND
ND
ND
NF
ND
ND
106.18
ND
34.39
ND
ND
ND
159.54
AA7
0.317
ND
43.72
ND
ND
ND
ND
5.49
ND
ND
728.23
ND
243.73
ND
ND
ND
1,021.17
AA8
0.324
ND
4.38
ND
ND
ND
ND
14.50
ND
ND
248.02
ND
45.20
ND
ND
ND
312.10
AA10
0.272
ND
11.02
ND
ND
ND
ND
NF
ND
ND
284.35
ND
103.53
ND
ND
ND
398.89
AA11
0.249
ND
16.88
ND
ND
ND
ND
5.28
ND
ND
70.04
ND
44.63
ND
ND
ND
136.83
AA12
0.270
ND
16.01
ND
ND
ND
ND
22.83
ND
ND
248.26
ND
38.55
ND
ND
ND
325.65
AA13
0.269
ND
16.53
ND
ND
ND
ND
4.26
ND
ND
20.14
ND
4.47
ND
ND
ND
45.41
AA14
0.289
ND
28.49
ND
ND
ND
ND
1.30
ND
ND
210.22
ND
59.68
ND
ND
ND
299.68
AA15
0.299
ND
4.07
ND
ND
ND
ND
20.11
ND
ND
351.99
ND
141.77
ND
ND
ND
517.93
AA16
0.345
ND
6.28
ND
ND
ND
ND
1.69
ND
ND
44.37
ND
19.59
ND
ND
ND
71.94
AA17
0.298
ND
33.88
ND
ND
ND
ND
14.32
ND
ND
135.21
ND
17.07
ND
ND
ND
200.47
AA18
0.299
ND
19.29
ND
ND
ND
ND
2.69
ND
ND
34.00
ND
1.21
ND
ND
ND
57.19
AA19
0.263
ND
2.51
ND
ND
ND
ND
5.32
ND
ND
171.89
ND
36.87
ND
ND
ND
216.60
Mean
0.30
 
15.08
    
9.46
  
234.59
 
73.87
 
18.09
 
333.96
SD
0.03
 
11.64
    
7.93
  
187.28
 
70.29
 
4.69
 
261.24
SEM
0.01
 
2.74
    
1.87
  
44.14
 
16.57
 
1.11
 
61.57
CA1
0.267
ND
39.42
ND
ND
ND
ND
39.50
ND
ND
350.35
ND
120.01
ND
ND
ND
549.27
CA2
0.283
ND
16.31
ND
ND
ND
ND
5.35
ND
ND
118.71
ND
385.77
ND
ND
ND
526.13
CA3
0.268
ND
37.05
ND
ND
ND
ND
44.14
ND
ND
131.34
ND
146.55
ND
ND
ND
359.08
CA4
0.328
ND
12.71
ND
ND
ND
ND
38.10
ND
ND
221.08
ND
615.33
ND
ND
ND
887.22
CA5
0.260
ND
6.87
ND
ND
ND
ND
27.61
ND
ND
50.04
ND
100.53
ND
ND
ND
185.05
CA6
0.294
ND
22.91
ND
ND
ND
ND
23.82
ND
ND
85.70
ND
36.74
ND
19.25
ND
188.41
CA7
0.295
ND
49.19
ND
ND
ND
ND
NF
ND
ND
98.10
ND
32.98
ND
40.37
ND
220.63
CA8
0.260
ND
23.83
ND
ND
ND
ND
10.86
ND
ND
34.00
ND
128.15
ND
ND
ND
196.85
CA9
0.255
ND
26.86
ND
ND
ND
ND
54.25
ND
ND
266.36
ND
153.19
ND
ND
ND
500.66
CA10
0.324
ND
15.30
ND
ND
ND
ND
10.95
ND
ND
61.18
ND
79.33
ND
ND
ND
166.76
CA12
0.305
ND
45.37
ND
ND
ND
ND
16.33
ND
ND
158.05
ND
106.95
ND
ND
ND
326.70
CA14
0.208
ND
67.15
ND
ND
ND
ND
25.67
ND
ND
337.20
ND
106.82
ND
ND
ND
536.84
CA15
0.258
ND
25.99
ND
ND
ND
ND
31.21
ND
ND
167.88
ND
64.90
ND
ND
ND
289.98
CA16
0.319
ND
32.34
ND
ND
ND
ND
26.20
ND
ND
351.61
ND
163.97
ND
ND
ND
574.12
CA17
0.310
ND
17.61
ND
ND
ND
ND
5.73
ND
ND
135.22
ND
69.24
ND
ND
ND
227.80
CA18
0.297
ND
101.07
ND
ND
ND
ND
63.23
ND
ND
174.84
ND
66.20
ND
ND
ND
405.34
CA19
0.323
ND
9.35
ND
ND
ND
ND
17.33
ND
ND
63.77
ND
46.59
ND
ND
ND
137.03
CA20
0.312
ND
19.01
ND
ND
ND
ND
26.06
ND
ND
78.28
ND
57.49
ND
ND
ND
180.83
Mean
0.29
 
31.57
    
27.43
  
160.21
 
137.82
 
29.81
 
358.82
SD
0.03
 
23.25
    
16.40
  
104.55
 
143.23
 
14.94
 
201.33
SEM
0.01
 
5.48
    
3.87
  
24.64
 
33.76
 
3.52
 
47.45
ND = not detected; SEM = standard error of the mean.
Of the 15 estrogen metabolites measured, only 5 were readily detectable as intrinsic components of breast tissue: estrone, estradiol, estriol, 2-methoxyestrone, and 2-hydroxyestradiol (Table 5). Estradiol, estriol and 2-methoxyestrone were significantly higher in the CAU breast tissue (P < 0.005), which was unanticipated given that previous studies have shown that premenopausal AA women have higher plasma concentrations of estrogens [40, 41]. Additionally, tissue levels of 2-hydroxyestradiol, a known carcinogen, were also detected in two patient samples, one from each group (Table 5, mean pg/g = 18.1 ± 4.7 for AA and 29.8 ± 14.9 for CAU). The data presented here advocate for a more intensive analysis of the hormonal milieu of the breast microenvironment in addition to plasma levels, since local hormones are directly responsible for mediating cellular function and influence tumorigenesis.

Discussion

This report is the first to analyze differences in the normal breast microenvironment of premenopausal women, and to show fundamental differences in the ability of breast ECM to influence the aggressiveness and tumorigenicity of breast cancer cells. The comprehensive LC-MS/MS identification of whole tissue hormone metabolites, as well as unique ECM proteins between the AA and CAU women, offers a novel insight into the intricacy of the breast microenvironment.
One limitation of this study, which must be addressed, is the lack of descriptive clinical data on the breast tissue isolated from the reduction mammoplasty patients. The tissue collected for fibroblast and whole breast tissue ECM isolation were considered pathological medical waste; therefore, informative clinical data including parity, body mass index, breast density, oral contraceptive use, phase of menstrual cycle were not available. Whether these important factors potentially had confounding effects on the observed results is regrettably unknown. In attempts to limit these effects, each experiment contained multiple replicates, and was repeated using as many different pools of patient samples feasible. A total of 50 CAU and 53 AA samples were used in the different analyses. However, the possibility remains that inherent factors from the tissue source could remain. Furthermore, we obtained samples from southern, eastern, and midwestern US, which may help eliminate the effects of socioeconomic factors if the samples had been obtained from one small geographical region. Determining whether clinical factors, or genetics, or a combination of the two, systematically relate as to why AAs develop a more aggressive cancer is not the purpose of this study. The objective of this study was not to determine how these discrepancies develop, but rather to use the information obtained to study their influence on breast cancer behavior. In addition, patient samples were pooled in order to obtain sufficient amount of ECM to perform these experiments. Although pooled samples are not ideal, a consistent pattern was observed with all results obtained even in this potentially confounding situation. Since no patient sample could be used twice, this suggests that our conclusions were not skewed by any single sample. Future studies to determine specific components in ECM responsible for these effects will require examination of individual tissues, if enough material becomes available from a single patient. Overall, the results presented provide valuable data for further investigation into the role of the microenvironment in cancer disparities, and potentially as a basis for future studies investigating factors such as parity and phase of menstrual cycle on breast cancer cell behavior.
Collectively, the data presented in this report suggest that the AA breast microenvironment is less permissive of tumor growth compared to the CAU breast microenvironment. Therefore, it is not surprising that only the more aggressive cells are able to survive and proliferate unrestrictedly in the suppressive microenvironment of AA breast tissue. The comparatively suppressive effects of the AA ECM may arise from both a physical restriction due to the types of structural material present in the ECM, and chemically from the signals present, or absent, in the microenvironment. Numerous reports have indicated that the spatial organization and composition of the ECM influence mammary cell behavior, and that alterations in ECM receptor expression facilitate malignant transformation [42].
The premenopausal stroma is not a static compartment; proliferation in the breast varies with the menstrual cycle, which requires the expansion and deposition of new ECM [43]. Increased deposition of molecules such as collagen can alter the ECM biophysical properties and increase extracellular cellular tension. ECM composition and rigidity modulate cell-ECM interactions and have a significant impact on cell functions. Indeed, mammary epithelial cells cultured on matrices with increased stiffness have disrupted cell-cell junctions, increased proliferation, perturbed endogenous basement membrane assembly, and a dedifferentiated phenotype [44, 45]. The development of breast cancer is characterized by the loss of tissue organization and an increase in tissue rigidity, suggesting that aberrant tension may facilitate the acquisition of a malignant phenotype [45]. For example, primary mammary epithelial cells cultured on floating collagen gels were shown to differentiate in response to lactogenic hormones only when plated on collagen gels with reduced tensional forces. When plated on gels with increased tension, the extracellular forces promoted cell spreading, increased MMP activity, and inhibited acini formation and cellular differentiation [46]. Interestingly, triple-negative tumors (ER-/PR- and lacking HER2 amplification) are composed of undifferentiated cells, potentially resulting from a small, localized area of matrix stiffness and high tension. Paszek et al. demonstrated that matrix stiffness promotes tumor-like behavior in mammary cells, and blocking integrin-dependent cell contractility reverted the malignant phenotype in culture [44]. Thus, if the premenopausal AA microenvironment is comparatively more restrictive in its composition/organization, as our data suggests, this may predispose AAs to triple-negative breast cancer. Further studies on this topic are warranted.
The use of a selective pressure to isolate a more tumorigenic cell is often used in studies seeking to identify the progenitor tumor-initiating cells (cancer stem cell) via culturing the cells in non-adherent conditions [47]. The rationale driving this culture system is that only the progenitor tumor-initiating cells are able to survive and self-renew when contact with the ECM is disrupted, whereas differentiated, non-tumor initiating cells experience anoikis and die [48]. Potentially a similar mechanism of selective pressure is actively selecting for the more aggressive cancer cell in the restrictive premenopausal AA microenvironment.
It is noteworthy that the invasiveness, tumorigenicity, and metastases of the ER+/PR+ cells were enhanced in the presence of the CAU ECM. It has been similarly shown that breast cancer cell proliferation, in response to androgens, was dependent upon both the ER status of the cell and signals from the ECM. Specifically, ER+ MCF7 cells proliferated in the presence of dihydrotestosterone (DHT) by an ERα-dependent mechanism; however, MDA-MB-231 cells responded to DHT by an ER-independent, αvβ3 integrin pathway [49]. Additional estrogen and ECM/integrin interactions related to tumorigenesis have been reported. Hypoxia-inducible factor 1α (HIF-1α), a transcription factor which is overexpressed in the majority of human carcinomas and controls central metastasis-associated pathways, was shown to increase anchorage-independent growth by downregulation of the α5 integrin [50]. Anchorage independent growth and decreased α5 integrin levels were reverted by treatment with the estrogen metabolite, 2-methoxyestradiol, a known pharmacological inhibitor of HIF-1α.
This is the first report to simultaneously analyze the biologically-active estrogens and androgens from each patient in whole breast tissue via LC-MS/MS; previous studies measured blood and urine levels. This method offers a more intimate analysis of the local hormone milieu of the breast microenvironment, compared to measuring circulating levels of hormones. Indeed, it is now well known that the local synthesis from the stromal cells dramatically contributes to the growth, function, and tumorigenesis of ER/PR positive and negative breast cells [5153]. BRCA1 tumors, the majority of which are ER-, have been effectively prevented by ovariectomy [54]. Furthermore, it is proposed that the increased risk of breast cancer following pregnancy is due to high levels of estrogen and other pregnancy associated hormones that promote the growth of already initiated target cell populations [55]. Interestingly, the majority of breast cancers that develop during this time are ER-/PR- suggesting that hormones affect the local microenvironment.
Different estrogen metabolites have been reported to act as either carcinogens or to protect from tumorigenesis, although their precise mechanisms are yet to be fully defined. The production of 16α-hydroxyestrone has been hypothesized to initiate breast cell transformation by acting as an estrogen agonist, increasing cellular proliferation and generating reactive oxygen species thereby causing DNA damage [56]. Conversely, 2-hydroxyestradiol has been shown to possess estrogen antagonist properties in vivo [56]. In this report, the primary estradiol/estrone metabolites detected were estriol, a product of the 16α-hydroxylation pathway, and 2-methoxyestrone, a product of the 2-hydroxylation pathway. It is of note that these two metabolites appear to be equally balanced in the tissue, as it has been shown that alterations in the ratio of C2/C16 estradiol/estrone hydroxylation can lead to anchorage-independent growth and tumorigenesis [57]. Analysis of these hormone metabolites in breast tissue, as opposed to circulating levels, could potentially be used for early detection of breast cancer in high-risk patients.
Our understanding of the interactions between the numerous cell types within breast, especially during tumorigenesis, still remains vague owing to the complexity of physical and chemical communication, and inherent differences between patients and their resultant types of cancer. However, apart from individual patient differences, there is indisputable evidence that breast carcinomas in premenopausal AA women tend to be triple negative and highly metastatic compared to breast carcinomas in CAU women. Identifying the initiating factors in the development of triple-negative breast cancer in premenopausal AA women will fill a gap of knowledge in breast cancer research. Why these women should have an increased incidence of this disease compared to other racial groups remains elusive.

Conclusions

This report details the importance of the normal breast microenvironment on breast cancer cell behavior, an essential step in the investigation of the etiology of breast cancer. The data presented characterize the composition of normal premenopausal breast tissue and provides data for further investigation into the role of the microenvironment in cancer disparities.

Acknowledgements

The authors would like to thank the NCI Frederick Pathology Histotechnology Laboratory for pathological examination of animal tissues and imaging of metastatic lesions.
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://​creativecommons.​org/​licenses/​by/​2.​0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

BKV and JMF conceived the project and designed all experiments. JMF performed all experiments and wrote the manuscript in consultation with BKV. TCM assisted in animal studies and qRT-PCR. MQ performed IPA and proteomic computational analyses. ZX and XX developed and performed MS procedures. MJM performed FACS. EG edited the manuscript and assisted in experiments. TDV assisted in the design and method of all MS procedures. All authors contributed to the analysis of data.
Anhänge

Electronic supplementary material

Additional file 1: Supplementary table and figures. Table S1: Real-time PCR primer sequences. Figure S1. Tumor characterization. (a,b) Humanized murine mammary glands, injected with primary metastatic breast cancer cells were stained for Ki67 (a). Bar = 200 μm. Percentage proliferation: number of positive per total live cells in a minimum of three fields. (b) Representative hematoxylin and eosin (H&E)-stained section. Bar = 2,000 μm. Overt necrosis was determined using AxioVision Imaging software version 4.8. Data represent mean ± standard error. AA = African-American, CAU = Caucasian-American. Figure S2. Validation of qPCR arrays. Breast fibroblasts pools, derived from a minimum of three age-matched patients, were analyzed per array. Graphs represent fold increase of differentially regulated genes. Figure S3. Soft agar growth assay. Cell lines were assayed and stained with nitrobluetetrazolium before counting. Representative images of a minimum of two experiments per cell line. Bar = 200 μm. Figure S4. Representative MS/MS spectra of peptides identified from breast tissue ECM proteins. A = hornerin; B = wnt10a; C = vimentin; D = cytokeratin 19. Figure S5. In silico analysis in African-American extracellular matrix protein molecules. (a-d) Top signaling network of unique proteins. Mapped identifiers (shown in gray) were overlaid onto a global molecular network developed from information contained in the Ingenuity knowledge base. Networks were then algorithmically generated based on their connectivity and incorporated with other molecules with high connectivity (white). Nodes associated with breast cancer according to the IPA knowledge base, are utlined in yellow. Figure S6. In silico analysis in Caucasian-American extracellular matrix protein molecules. (a-d) As for Figure S5. (PPT 11 MB)
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.CrossRefPubMed Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.CrossRefPubMed
2.
Zurück zum Zitat Dong-Le Bourhis X, Berthois Y, Millot G, Degeorges A, Sylvi M, Martin PM, Calvo F: Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer. 1997, 71: 42-48. 10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3.CrossRefPubMed Dong-Le Bourhis X, Berthois Y, Millot G, Degeorges A, Sylvi M, Martin PM, Calvo F: Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer. 1997, 71: 42-48. 10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3.CrossRefPubMed
3.
Zurück zum Zitat Sadlonova A, Novak Z, Johnson MR, Bowe DB, Gault SR, Page GP, Thottassery JV, Welch DR, Frost AR: Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res. 2005, 7: R46-59. 10.1186/bcr949.CrossRefPubMed Sadlonova A, Novak Z, Johnson MR, Bowe DB, Gault SR, Page GP, Thottassery JV, Welch DR, Frost AR: Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res. 2005, 7: R46-59. 10.1186/bcr949.CrossRefPubMed
4.
Zurück zum Zitat Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L: Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res. 2001, 61: 1320-1326.PubMed Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L: Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res. 2001, 61: 1320-1326.PubMed
5.
Zurück zum Zitat van Roozendaal KE, Klijn JG, van Ooijen B, Claassen C, Eggermont AM, Henzen-Logmans SC, Foekens JA: Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer. 1996, 65: 120-125. 10.1002/(SICI)1097-0215(19960103)65:1<120::AID-IJC20>3.0.CO;2-J.CrossRefPubMed van Roozendaal KE, Klijn JG, van Ooijen B, Claassen C, Eggermont AM, Henzen-Logmans SC, Foekens JA: Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer. 1996, 65: 120-125. 10.1002/(SICI)1097-0215(19960103)65:1<120::AID-IJC20>3.0.CO;2-J.CrossRefPubMed
6.
Zurück zum Zitat Barcellos-Hoff MH, Ravani SA: Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 2000, 60: 1254-1260.PubMed Barcellos-Hoff MH, Ravani SA: Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 2000, 60: 1254-1260.PubMed
7.
Zurück zum Zitat Proia DA, Kuperwasser C: Stroma: tumor agonist or antagonist. Cell Cycle. 2005, 4: 1022-1025.CrossRefPubMed Proia DA, Kuperwasser C: Stroma: tumor agonist or antagonist. Cell Cycle. 2005, 4: 1022-1025.CrossRefPubMed
8.
Zurück zum Zitat Sadlonova A, Mukherjee S, Bowe DB, Gault SR, Dumas NA, Van Tine BA, Frolova N, Page GP, Welch DR, Novak L, Frost AR: Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease. Am J Pathol. 2007, 170: 1064-1076. 10.2353/ajpath.2007.060031.CrossRefPubMedPubMedCentral Sadlonova A, Mukherjee S, Bowe DB, Gault SR, Dumas NA, Van Tine BA, Frolova N, Page GP, Welch DR, Novak L, Frost AR: Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease. Am J Pathol. 2007, 170: 1064-1076. 10.2353/ajpath.2007.060031.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A, Violette S, Nikolskaya T, Nikolsky Y, Bauerlein EL, Hahn WC, Gelman RS, Allred C, Bissell MJ, Schnitt S, Polyak K: Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008, 13: 394-406. 10.1016/j.ccr.2008.03.007.CrossRefPubMedPubMedCentral Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A, Violette S, Nikolskaya T, Nikolsky Y, Bauerlein EL, Hahn WC, Gelman RS, Allred C, Bissell MJ, Schnitt S, Polyak K: Regulation of in situ to invasive breast carcinoma transition. Cancer Cell. 2008, 13: 394-406. 10.1016/j.ccr.2008.03.007.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Booth BW, Mack DL, Androutsellis-Theotokis A, McKay RD, Boulanger CA, Smith GH: The mammary microenvironment alters the differentiation repertoire of neural stem cells. Proc Natl Acad Sci USA. 2008, 105: 14891-14896. 10.1073/pnas.0803214105.CrossRefPubMedPubMedCentral Booth BW, Mack DL, Androutsellis-Theotokis A, McKay RD, Boulanger CA, Smith GH: The mammary microenvironment alters the differentiation repertoire of neural stem cells. Proc Natl Acad Sci USA. 2008, 105: 14891-14896. 10.1073/pnas.0803214105.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Boulanger CA, Mack DL, Booth BW, Smith GH: Interaction with the mammary microenvironment redirects spermatogenic cell fate in vivo. Proc Natl Acad Sci USA. 2007, 104: 3871-3876. 10.1073/pnas.0611637104.CrossRefPubMedPubMedCentral Boulanger CA, Mack DL, Booth BW, Smith GH: Interaction with the mammary microenvironment redirects spermatogenic cell fate in vivo. Proc Natl Acad Sci USA. 2007, 104: 3871-3876. 10.1073/pnas.0611637104.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Parise CA, Bauer KR, Brown MM, Caggiano V: Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009, 15: 593-602. 10.1111/j.1524-4741.2009.00822.x.CrossRefPubMed Parise CA, Bauer KR, Brown MM, Caggiano V: Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009, 15: 593-602. 10.1111/j.1524-4741.2009.00822.x.CrossRefPubMed
13.
Zurück zum Zitat Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V: The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 2008, 112: 737-747. 10.1002/cncr.23243.CrossRefPubMed Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V: The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 2008, 112: 737-747. 10.1002/cncr.23243.CrossRefPubMed
14.
Zurück zum Zitat Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007, 109: 1721-1728. 10.1002/cncr.22618.CrossRefPubMed Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007, 109: 1721-1728. 10.1002/cncr.22618.CrossRefPubMed
15.
Zurück zum Zitat Parise CA, Bauer KR, Caggiano V: Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol. Parise CA, Bauer KR, Caggiano V: Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol.
16.
Zurück zum Zitat Hunter CP: Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer. 2000, 88: 1193-1202. 10.1002/(SICI)1097-0142(20000301)88:5+<1193::AID-CNCR3>3.0.CO;2-D.CrossRefPubMed Hunter CP: Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer. 2000, 88: 1193-1202. 10.1002/(SICI)1097-0142(20000301)88:5+<1193::AID-CNCR3>3.0.CO;2-D.CrossRefPubMed
17.
Zurück zum Zitat Rose DP, Haffner SM, Baillargeon J: Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev. 2007, 28: 763-777. 10.1210/er.2006-0019.CrossRefPubMed Rose DP, Haffner SM, Baillargeon J: Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev. 2007, 28: 763-777. 10.1210/er.2006-0019.CrossRefPubMed
18.
Zurück zum Zitat Newman LA, Mason J, Cote D, Vin Y, Carolin K, Bouwman D, Colditz GA: African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer. 2002, 94: 2844-2854. 10.1002/cncr.10575.CrossRefPubMed Newman LA, Mason J, Cote D, Vin Y, Carolin K, Bouwman D, Colditz GA: African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer. 2002, 94: 2844-2854. 10.1002/cncr.10575.CrossRefPubMed
19.
Zurück zum Zitat Ijaduola TG, Smith EB: Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J Natl Med Assoc. 1998, 90: 547-551.PubMedPubMedCentral Ijaduola TG, Smith EB: Pattern of breast cancer among white-American, African-American, and nonimmigrant west-African women. J Natl Med Assoc. 1998, 90: 547-551.PubMedPubMedCentral
20.
Zurück zum Zitat Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.CrossRefPubMedPubMedCentral Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003, 100: 3983-3988. 10.1073/pnas.0530291100.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990, 50: 6075-6086.PubMed Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990, 50: 6075-6086.PubMed
22.
Zurück zum Zitat Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES, Lisanti MP: Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther. 2008, 7: 1212-1225. 10.4161/cbt.7.8.6220.CrossRefPubMed Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES, Lisanti MP: Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther. 2008, 7: 1212-1225. 10.4161/cbt.7.8.6220.CrossRefPubMed
23.
Zurück zum Zitat Schedin P, Mitrenga T, McDaniel S, Kaeck M: Mammary ECM composition and function are altered by reproductive state. Mol Carcinog. 2004, 41: 207-220. 10.1002/mc.20058.CrossRefPubMed Schedin P, Mitrenga T, McDaniel S, Kaeck M: Mammary ECM composition and function are altered by reproductive state. Mol Carcinog. 2004, 41: 207-220. 10.1002/mc.20058.CrossRefPubMed
24.
Zurück zum Zitat Fleming JM, Long EL, Ginsburg E, Gerscovich D, Meltzer PS, Vonderhaar BK: Interlobular and intralobular mammary stroma: genotype may not reflect phenotype. BMC Cell Biol. 2008, 9: 46-10.1186/1471-2121-9-46.CrossRefPubMedPubMedCentral Fleming JM, Long EL, Ginsburg E, Gerscovich D, Meltzer PS, Vonderhaar BK: Interlobular and intralobular mammary stroma: genotype may not reflect phenotype. BMC Cell Biol. 2008, 9: 46-10.1186/1471-2121-9-46.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Proia DA, Kuperwasser C: Reconstruction of human mammary tissues in a mouse model. Nat Protoc. 2006, 1: 206-214. 10.1038/nprot.2006.31.CrossRefPubMed Proia DA, Kuperwasser C: Reconstruction of human mammary tissues in a mouse model. Nat Protoc. 2006, 1: 206-214. 10.1038/nprot.2006.31.CrossRefPubMed
26.
Zurück zum Zitat McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, Schedin P: Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol. 2006, 168: 608-620. 10.2353/ajpath.2006.050677.CrossRefPubMedPubMedCentral McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, Schedin P: Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol. 2006, 168: 608-620. 10.2353/ajpath.2006.050677.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA: Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA. 2004, 101: 4966-4971. 10.1073/pnas.0401064101.CrossRefPubMedPubMedCentral Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA: Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA. 2004, 101: 4966-4971. 10.1073/pnas.0401064101.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Hu M, Polyak K: Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer. 2008, 44: 2760-2765. 10.1016/j.ejca.2008.09.038.CrossRefPubMedPubMedCentral Hu M, Polyak K: Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer. 2008, 44: 2760-2765. 10.1016/j.ejca.2008.09.038.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Stuelten CH, Barbul A, Busch JI, Sutton E, Katz R, Sato M, Wakefield LM, Roberts AB, Niederhuber JE: Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism. Cancer Res. 2008, 68: 7278-7282. 10.1158/0008-5472.CAN-08-1842.CrossRefPubMedPubMedCentral Stuelten CH, Barbul A, Busch JI, Sutton E, Katz R, Sato M, Wakefield LM, Roberts AB, Niederhuber JE: Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism. Cancer Res. 2008, 68: 7278-7282. 10.1158/0008-5472.CAN-08-1842.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Nicolini A, Carpi A: Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev. 2009, 29: 436-71. 10.1002/med.20143.CrossRefPubMed Nicolini A, Carpi A: Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology. Med Res Rev. 2009, 29: 436-71. 10.1002/med.20143.CrossRefPubMed
31.
Zurück zum Zitat Groblewska M, Mroczko B, Czygier M, Szmitkowski M: Cytokines as markers of osteolysis in the diagnostics of patients with bone metastases [in Polish]. Postepy Hig Med Dosw (Online). 2008, 62: 668-675. Groblewska M, Mroczko B, Czygier M, Szmitkowski M: Cytokines as markers of osteolysis in the diagnostics of patients with bone metastases [in Polish]. Postepy Hig Med Dosw (Online). 2008, 62: 668-675.
32.
Zurück zum Zitat Ronnov-Jessen L, Bissell MJ: Breast cancer by proxy: can the microenvironment be both the cause and consequence?. Trends Mol Med. 2009, 15: 5-13. 10.1016/j.molmed.2008.11.001.CrossRefPubMed Ronnov-Jessen L, Bissell MJ: Breast cancer by proxy: can the microenvironment be both the cause and consequence?. Trends Mol Med. 2009, 15: 5-13. 10.1016/j.molmed.2008.11.001.CrossRefPubMed
33.
Zurück zum Zitat Brummer O, Athar S, Riethdorf L, Loning T, Herbst H: Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch. 1999, 435: 566-573. 10.1007/s004280050442.CrossRefPubMed Brummer O, Athar S, Riethdorf L, Loning T, Herbst H: Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch. 1999, 435: 566-573. 10.1007/s004280050442.CrossRefPubMed
34.
Zurück zum Zitat Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997, 277: 225-228. 10.1126/science.277.5323.225.CrossRefPubMed Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997, 277: 225-228. 10.1126/science.277.5323.225.CrossRefPubMed
35.
Zurück zum Zitat Schedin P, Strange R, Mitrenga T, Wolfe P, Kaeck M: Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J Cell Sci. 2000, 113: 795-806.PubMed Schedin P, Strange R, Mitrenga T, Wolfe P, Kaeck M: Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J Cell Sci. 2000, 113: 795-806.PubMed
36.
Zurück zum Zitat Xiao Z, Blonder J, Zhou M, Veenstra TD: Proteomic analysis of extracellular matrix and vesicles. J Proteomics. 2009, 72: 34-45. 10.1016/j.jprot.2008.11.011.CrossRefPubMed Xiao Z, Blonder J, Zhou M, Veenstra TD: Proteomic analysis of extracellular matrix and vesicles. J Proteomics. 2009, 72: 34-45. 10.1016/j.jprot.2008.11.011.CrossRefPubMed
37.
Zurück zum Zitat Stern DF: ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 2008, 13: 215-223. 10.1007/s10911-008-9083-7.CrossRefPubMed Stern DF: ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 2008, 13: 215-223. 10.1007/s10911-008-9083-7.CrossRefPubMed
38.
Zurück zum Zitat Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA: Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol. 2009, 24: 385-398.PubMed Zardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA: Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol. 2009, 24: 385-398.PubMed
39.
Zurück zum Zitat Kronenberg H, Williams RH: Williams textbook of endocrinology. 2008, Philadelphia, PA, USA: Saunders/Elsevier, 11 Kronenberg H, Williams RH: Williams textbook of endocrinology. 2008, Philadelphia, PA, USA: Saunders/Elsevier, 11
40.
Zurück zum Zitat Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE: Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev. 2005, 14: 2147-2153. 10.1158/1055-9965.EPI-04-0944.CrossRefPubMed Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE: Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev. 2005, 14: 2147-2153. 10.1158/1055-9965.EPI-04-0944.CrossRefPubMed
41.
Zurück zum Zitat Woods MN, Barnett JB, Spiegelman D, Trail N, Hertzmark E, Longcope C, Gorbach SL: Hormone levels during dietary changes in premenopausal African-American women. J Natl Cancer Inst. 1996, 88: 1369-1374. 10.1093/jnci/88.19.1369.CrossRefPubMed Woods MN, Barnett JB, Spiegelman D, Trail N, Hertzmark E, Longcope C, Gorbach SL: Hormone levels during dietary changes in premenopausal African-American women. J Natl Cancer Inst. 1996, 88: 1369-1374. 10.1093/jnci/88.19.1369.CrossRefPubMed
42.
Zurück zum Zitat Ingber DE: Can cancer be reversed by engineering the tumor microenvironment?. Semin Cancer Biol. 2008, 18: 356-364. 10.1016/j.semcancer.2008.03.016.CrossRefPubMedPubMedCentral Ingber DE: Can cancer be reversed by engineering the tumor microenvironment?. Semin Cancer Biol. 2008, 18: 356-364. 10.1016/j.semcancer.2008.03.016.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, Potten CS: Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer. 1991, 48: 206-210. 10.1002/ijc.2910480209.CrossRefPubMed Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA, Potten CS: Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer. 1991, 48: 206-210. 10.1002/ijc.2910480209.CrossRefPubMed
44.
Zurück zum Zitat Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM: Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005, 8: 241-254. 10.1016/j.ccr.2005.08.010.CrossRefPubMed Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM: Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005, 8: 241-254. 10.1016/j.ccr.2005.08.010.CrossRefPubMed
45.
Zurück zum Zitat Alcaraz J, Xu R, Mori H, Nelson CM, Mroue R, Spencer VA, Brownfield D, Radisky DC, Bustamante C, Bissell MJ: Laminin and biomimetic extracellular elasticity enhance functional differentiation in mammary epithelia. EMBO J. 2008, 27: 2829-2838. 10.1038/emboj.2008.206.CrossRefPubMedPubMedCentral Alcaraz J, Xu R, Mori H, Nelson CM, Mroue R, Spencer VA, Brownfield D, Radisky DC, Bustamante C, Bissell MJ: Laminin and biomimetic extracellular elasticity enhance functional differentiation in mammary epithelia. EMBO J. 2008, 27: 2829-2838. 10.1038/emboj.2008.206.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ: Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development. 1989, 105: 223-235.PubMedPubMedCentral Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ: Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development. 1989, 105: 223-235.PubMedPubMedCentral
47.
Zurück zum Zitat Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou J, Burchell JM: Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008, 10: R52-10.1186/bcr2106.CrossRefPubMedPubMedCentral Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou J, Burchell JM: Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008, 10: R52-10.1186/bcr2106.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Reynolds BA, Weiss S: Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol. 1996, 175: 1-13. 10.1006/dbio.1996.0090.CrossRefPubMed Reynolds BA, Weiss S: Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol. 1996, 175: 1-13. 10.1006/dbio.1996.0090.CrossRefPubMed
49.
Zurück zum Zitat Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, Davis FB, Davis PJ: Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol. 2009, 113: 182-188. 10.1016/j.jsbmb.2008.12.010.CrossRefPubMed Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, Davis FB, Davis PJ: Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J Steroid Biochem Mol Biol. 2009, 113: 182-188. 10.1016/j.jsbmb.2008.12.010.CrossRefPubMed
50.
Zurück zum Zitat Rohwer N, Lobitz S, Daskalow K, Jons T, Vieth M, Schlag PM, Kemmner W, Wiedenmann B, Cramer T, Hocker M: HIF-1a determines the metastatic potential of gastric cancer cells. Br J Cancer. 2009, 100: 772-781. 10.1038/sj.bjc.6604919.CrossRefPubMedPubMedCentral Rohwer N, Lobitz S, Daskalow K, Jons T, Vieth M, Schlag PM, Kemmner W, Wiedenmann B, Cramer T, Hocker M: HIF-1a determines the metastatic potential of gastric cancer cells. Br J Cancer. 2009, 100: 772-781. 10.1038/sj.bjc.6604919.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, Kuperwasser C: Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 2007, 67: 2062-2071. 10.1158/0008-5472.CAN-06-3895.CrossRefPubMed Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, Kuperwasser C: Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res. 2007, 67: 2062-2071. 10.1158/0008-5472.CAN-06-3895.CrossRefPubMed
52.
Zurück zum Zitat Armitage P, Doll R: The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 2004, 91: 1983-1989. 10.1038/sj.bjc.6602297.CrossRefPubMedPubMedCentral Armitage P, Doll R: The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 2004, 91: 1983-1989. 10.1038/sj.bjc.6602297.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Haslam SZ, Woodward TL: Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Res. 2003, 5: 208-215. 10.1186/bcr615.CrossRefPubMedPubMedCentral Haslam SZ, Woodward TL: Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Res. 2003, 5: 208-215. 10.1186/bcr615.CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, Prevention and Observation of Surgical End Points Study Group: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002, 346: 1616-1622. 10.1056/NEJMoa012158.CrossRefPubMed Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, Prevention and Observation of Surgical End Points Study Group: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002, 346: 1616-1622. 10.1056/NEJMoa012158.CrossRefPubMed
55.
Zurück zum Zitat Lyons TR, Schedin PJ, Borges VF: Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia. 2009, 14: 87-98. 10.1007/s10911-009-9119-7.CrossRefPubMedPubMedCentral Lyons TR, Schedin PJ, Borges VF: Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia. 2009, 14: 87-98. 10.1007/s10911-009-9119-7.CrossRefPubMedPubMedCentral
56.
Zurück zum Zitat Mueck AO, Seeger H, Lippert TH: Estradiol metabolism and malignant disease. Maturitas. 2002, 43: 1-10. 10.1016/S0378-5122(02)00141-X.CrossRefPubMed Mueck AO, Seeger H, Lippert TH: Estradiol metabolism and malignant disease. Maturitas. 2002, 43: 1-10. 10.1016/S0378-5122(02)00141-X.CrossRefPubMed
57.
Zurück zum Zitat Suto A, Bradlow HL, Wong GY, Osborne MP, Telang NT: Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Breast Cancer Res Treat. 1993, 27: 193-202. 10.1007/BF00665689.CrossRefPubMed Suto A, Bradlow HL, Wong GY, Osborne MP, Telang NT: Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Breast Cancer Res Treat. 1993, 27: 193-202. 10.1007/BF00665689.CrossRefPubMed
Metadaten
Titel
The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo
verfasst von
Jodie M Fleming
Tyler C Miller
Mariam Quinones
Zhen Xiao
Xia Xu
Matthew J Meyer
Erika Ginsburg
Timothy D Veenstra
Barbara K Vonderhaar
Publikationsdatum
01.12.2010
Verlag
BioMed Central
Erschienen in
BMC Medicine / Ausgabe 1/2010
Elektronische ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-8-27

Weitere Artikel der Ausgabe 1/2010

BMC Medicine 1/2010 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.